Skip to main content
. Author manuscript; available in PMC: 2010 Aug 18.
Published in final edited form as: J Neuroimmunol. 2009 Jun 21;213(1-2):47–59. doi: 10.1016/j.jneuroim.2009.06.002

Figure 4.

Figure 4

Effects of PMS-601 on the NF-| B pathway activation and MAPK pathway. A Graphs of levels of p50, and p65 and phosphorylated NF-| B (p- NF-| B) in human MDM treated with increasing concentrations of PMS-601 as measured by MFI using in situ ELISA assay. B Confocal microscopy of anti-p-NF-| B in control human MDM, human MDM infected with HIV-1ADA and human MDM infected with HIV-1ADA treated with 1 mM PMS-601. C Graphs of levels of total ERK, total JNK, phosphorylated ERK (p-ERK) and phosphorylated JNK (p-JNK) in control human MDM and HIV-1ADA infected human MDM treated with increasing concentrations of PMS-601 as measured by MFI using in situ ELISA assay. In situ ELISA experiments are representative of 6 replicate assays performed with MDM from 3 different donors. Data are expressed as means ± S.E.M. * P≤0.05 ** P≤0.01 *** P≤0.001